Krt-232, A First-In-Class, Murine Double Minute 2 Inhibitor (Mdm2i), For Tp53 Wild-Type (P53(Wt)) Merkel Cell Carcinoma (Mcc) After Anti-Pd-1/L1 Immunotherapy.

Michael K.K. Wong,Ciara Marie Kelly,Melissa Amber Burgess,Karl Lewis,Jaspreet Singh Grewal,Anthony J. Olszanski,Jesse McGreivy,Wayne Rothbaum,Hope Qamoos,James A. DeCaprio

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 9|浏览1

暂无评分

摘要

10072Background: MCC is an aggressive neuroendocrine skin cancer with very poor prognosis. Immune checkpoint inhibition was recently shown to benefit some patients (pts). There are few effective tr...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要